Cargando…

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies

SIMPLE SUMMARY: Immunotherapy development in pediatric AML has been slow due to the paucity of validated AML-specific targets. We recently identified mesothelin (MSLN) as a therapeutic target in pediatric AML. Mice receiving T cell engaging bispecific antibodies (BsAbs) targeting MSLN and CD3 achiev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gopalakrishnapillai, Anilkumar, Correnti, Colin E., Pilat, Kristina, Lin, Ida, Chan, Man Kid, Bandaranayake, Ashok D., Mehlin, Christopher, Kisielewski, Anne, Hamill, Darcy, Kaeding, Allison J., Meshinchi, Soheil, Olson, James M., Kolb, Edward Anders, Barwe, Sonali P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657033/ https://www.ncbi.nlm.nih.gov/pubmed/34885074 http://dx.doi.org/10.3390/cancers13235964

Ejemplares similares

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
por: Lehner, Kara M., et al.
Publicado: (2023)

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2014)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology
por: Barwe, Sonali P., et al.
Publicado: (2020)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
por: Quagliano, Anthony, et al.
Publicado: (2020)

Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies
por: Quagliano, Anthony, et al.
Publicado: (2023)

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
por: Barwe, Sonali P., et al.
Publicado: (2022)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies
por: Sidhu, Ishnoor, et al.
Publicado: (2021)

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2015)

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2016)

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring
por: Crowgey, Erin L., et al.
Publicado: (2020)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome
por: Bloh, Kevin M., et al.
Publicado: (2017)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
por: Hatterer, Eric, et al.
Publicado: (2020)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Screening, large-scale production, and structure-based classification for cystine-dense peptides
por: Correnti, Colin E., et al.
Publicado: (2018)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
por: Köhnke, Thomas, et al.
Publicado: (2022)

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples
por: Barwe, Sonali P., et al.
Publicado: (2020)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Transcriptome Profiling of Pediatric Core Binding Factor AML
por: Hsu, Chih-Hao, et al.
Publicado: (2015)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

A B-cell developmental gene regulatory network is activated in infant AML
por: Bolouri, Hamid, et al.
Publicado: (2021)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cupq4rscbte3r97egjv8cs15np